Aspire Biopharma Holdings, Inc. — Form 8-K
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 25/100
What the filing says
Aspire Biopharma Holdings filed an 8-K on 2026-08-19 containing Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing references an exhibit (EX-99.1) with multiple graphics but the actual text content of the disclosure is not provided in the filing header/metadata supplied. Specific dollar amounts, counterparties, dates, and business impact cannot be determined from the available information.
Why this rating
No substantive disclosure details available in provided text; cannot assess materiality relative to $17.4M market cap without knowing what was actually disclosed.
Extracted items
- 7.01 Reg FD disclosure
- 9.01 exhibits
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.